What is the recommended dose of tranexamic acid (TXA) for heavy menstrual bleeding?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Tranexamic Acid Dosing for Heavy Menstrual Bleeding

For heavy menstrual bleeding, administer tranexamic acid 3.9 grams daily (typically divided into 2-3 doses) for up to 5 days during menstruation, starting on the first day of bleeding. 1, 2

Standard Dosing Regimen

  • The recommended oral dose is 3.9-4 grams per day, divided into multiple doses (typically 1.3 grams three times daily or 650 mg four times daily), taken for 4-5 days starting from the first day of menstruation. 1, 2, 3

  • This dosing regimen reduces menstrual blood loss by 26-60% compared to baseline and is significantly more effective than placebo, NSAIDs, or oral progestins. 2, 3

  • A dose-response study specifically demonstrated that the 3.9 g/day dose met all three primary efficacy endpoints (mean reduction in menstrual blood loss, meaningful reduction as judged by patients, and >50 mL reduction from baseline), while the lower 1.95 g/day dose was less effective. 4

Alternative Dosing for Specific Situations

  • For women with von Willebrand disease or severe refractory menorrhagia, higher doses up to 3 grams daily in four divided doses for the first 5 days may be necessary when standard dosing fails. 5

  • The standard 1 gram daily dose is insufficient for most patients with heavy menstrual bleeding and should not be used. 5

Duration and Timing

  • Treatment should be limited to 5 days maximum during each menstrual cycle, starting on the first day of bleeding. 1, 2, 4

  • The medication should be taken only during days of active bleeding, not throughout the entire menstrual cycle. 2, 3

Safety Considerations and Contraindications

  • Active thromboembolic disease is an absolute contraindication; in the United States, a history of thrombosis/thromboembolism or intrinsic risk for thrombosis is also considered a contraindication. 1, 2

  • Use with extreme caution in women taking oral contraceptives due to increased thrombotic risk—consider alternative therapy or discontinue one agent. 6, 7

  • Dose adjustment is required in renal dysfunction based on serum creatinine levels. 6, 7

  • Discontinue 5 days before high bleeding risk procedures or surgery in confined spaces. 6, 7

Clinical Efficacy Context

  • Tranexamic acid is more effective than NSAIDs (mefenamic acid, flurbiprofen), etamsylate, and oral luteal phase progestins for reducing menstrual blood loss. 2, 3

  • The levonorgestrel-releasing intrauterine system (LNG-IUS) produces greater reduction in menstrual blood loss (96% after 12 months) compared to tranexamic acid, though 44% of LNG-IUS users develop amenorrhea which may be unacceptable to some patients. 3

  • Combined oral contraceptives show comparable efficacy to tranexamic acid for heavy menstrual bleeding, with no statistically significant difference in mean blood loss reduction. 8

Adverse Effects

  • The most common adverse effects are gastrointestinal (nausea, vomiting, diarrhea, dyspepsia), occurring in approximately 12% of patients, which is not significantly different from placebo rates. 3

  • No evidence exists of increased incidence of thrombotic events with appropriate use in patients without contraindications. 2

  • Both the 3.9 g/day and 1.95 g/day doses were well tolerated with no serious study-related adverse events reported in clinical trials. 4

References

Guideline

Tranexamic Acid Dosing Recommendations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Tranexamic Acid Dosing for Fibroid-Related Bleeding

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Tranexamic Acid Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.